Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.95 -8.24% -0.18
ACRX closed down 8.24 percent on Monday, October 16, 2017, on 2.33 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 7

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACRX trend table...

Date Alert Name Type % Chg
Oct 16 New 52 Week Low Other 0.00%
Oct 16 Narrow Range Bar Range Contraction 0.00%
Oct 16 Stochastic Reached Oversold Other 0.00%
Oct 16 MACD Bearish Centerline Cross Bearish 0.00%
Oct 16 Calm After Storm Range Contraction 0.00%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.75
52 Week Low 1.95
Average Volume 2,274,882
200-Day Moving Average 2.9504
50-Day Moving Average 3.5171
20-Day Moving Average 4.1554
10-Day Moving Average 4.315
Average True Range 0.5172
ADX 43.42
+DI 22.93
-DI 46.27
Chandelier Exit (Long, 3 ATRs ) 4.1984
Chandelier Exit (Short, 3 ATRs ) 3.4516
Upper Bollinger Band 6.5023
Lower Bollinger Band 1.8085
Percent B (%b) 0.03
BandWidth 112.956635
MACD Line -0.0812
MACD Signal Line 0.2914
MACD Histogram -0.3726
Fundamentals Value
Market Cap 88.49 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.77
Price-to-Sales 14.72
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.33
Resistance 3 (R3) 2.35 2.25 2.26
Resistance 2 (R2) 2.25 2.15 2.24 2.24
Resistance 1 (R1) 2.10 2.10 2.05 2.08 2.22
Pivot Point 2.00 2.00 1.98 1.99 2.00
Support 1 (S1) 1.85 1.90 1.80 1.83 1.68
Support 2 (S2) 1.75 1.85 1.74 1.66
Support 3 (S3) 1.60 1.75 1.64
Support 4 (S4) 1.58